Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss
- 3 March 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 31 (4), 865-875
- https://doi.org/10.1681/asn.2019050497
Abstract
Background In males with classic Fabry disease, the processes leading to the frequent outcome of ESKD are poorly understood. Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types. In the glomerular podocytes, accumulation of GL3 progresses with age. Of concern, podocytes are relatively resistant to enzyme replacement therapy and are poorly replicating, with little ability to compensate for cell loss. Methods In this study of 55 males (mean age 27 years) with classic Fabry disease genotype and/or phenotype, we performed unbiased quantitative morphometric electron microscopic studies of biopsied kidney samples from patients and seven living transplant donors (to serve as controls). We extracted clinical information from medical records and clinical trial databases. Results Podocyte GL3 volume fraction (proportion of podocyte cytoplasm occupied by GL3) increased with age up to about age 27, suggesting that increasing podocyte GL3 volume fraction beyond a threshold may compromise survival of these cells. GL3 accumulation was associated with podocyte injury and loss, as evidenced by increased foot process width (a generally accepted structural marker of podocyte stress and injury) and with decreased podocyte number density per glomerular volume. Worsening podocyte structural parameters (increasing podocyte GL3 volume fraction and foot process width) was also associated with increasing urinary protein excretion—a strong prognosticator of adverse renal outcomes in Fabry disease—as well as with decreasing GFR. Conclusions Given the known association between podocyte loss and irreversible FSGS and global glomerulosclerosis, this study points to an important role for podocyte injury and loss in the progression of Fabry nephropathy and indicates a need for therapeutic intervention before critical podocyte loss occurs.Keywords
Funding Information
- Sanofi Genzyme
- National Center for Advancing Translational Sciences (U54NS065768)
This publication has 40 references indexed in Scilit:
- New Insights into the Pathology of Podocyte LossThe American Journal of Pathology, 2013
- Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationNephrology Dialysis Transplantation, 2011
- Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry diseaseKidney International, 2011
- Prognostic Indicators of Renal Disease Progression in Adults with Fabry DiseaseClinical Journal of the American Society of Nephrology, 2010
- Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry DiseaseJournal of the American Society of Nephrology, 2007
- Agalsidase-Beta Therapy for Advanced Fabry DiseaseAnnals of Internal Medicine, 2007
- Pathways to nephron loss starting from glomerular diseases—Insights from animal modelsKidney International, 2005
- The pathogenesis of 'classic' focal segmental glomerulosclerosis-lessons from rat models.Nephrology Dialysis Transplantation, 2003
- Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapyKidney International, 2002
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJournal of Medical Genetics, 2001